Ushering in the future of mental health

Our research platform empowers researchers, nonprofits, life sciences organizations, payers, and academic labs to accelerate mental health research, generate evidence, and unlock insights.

Trusted by top researchers in mental health and neuroscience
We are building the digital technology infrastructure and research engine for treatment-resistant mental health, precision mental health, psychiatry, FDA-approved psychedelic medicine, interventional psychiatry, and other innovative approaches within neuroscience and neurotech. We have a bold vision for the future — one in which mental health is no longer a worldwide crisis. To get there, we need all-hands-on-deck to advance mental health research and neuroscience.

For researchers, we offer:


Software including clinical trials e-source, research participant engagement, and multimodal data collection.



Real-world evidence platform that generates insights for researchers. We achieve both breadth and depth.


A sample of Osmind studies in progress

Psychedelic Integration Study

With our partner Fluence, we have launched a prospective observational study on psychedelic harm reduction and integration in naturalistic care settings. Please see the study website for more information.

ORKA (Osmind Real-world Ketamine Analysis)

In collaboration with preeminent experts at several top academic medical centers, we are assessing long-term patient outcomes throughout naturalistic repeated intravenous ketamine therapy in a very large sample of patients in the community.

Ketamine-mediated improvement of daily living

In collaboration with the Ketamine Taskforce for Access to Safe Care and Insurance Coverage, we are conducting a prospective study on how ketamine affects activities of daily living and other functional outcomes in CRPS patients.

KISSD (Ketamine Intramuscular Stepped System for Depression)

We are conducting a study on an innovative intramuscular racemic ketamine protocol to elucidate its efficacy and safety for the treatment of TRD, particularly around the relationship between dosage and time to relapse.

Let's revolutionize mental health together

Enabling cutting-edge research in academia, life sciences organizations, payers, and health systems. We're focused on advancing new therapeutics, precision diagnostics, and care management programs.
Learn more